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primary analysis tested the impact of mismatch at HLA-A, B,
C and DRB1. Secondary analyses examined HLA locus-speciﬁc
effects, allele vs. antigen mismatch, and the impact of DPB1
and DQB1 mismatch. Additional patient, disease, and HCT
variables were considered in multivariate analyses. A p value
< 0.01 was considered signiﬁcant.
Results: Of the study population (n¼8,003), cases were 8/8
(n¼5,449), 7/8 (n¼2,071), or 6/8 (n¼483) matched. Median
follow up for surviving patients was 49 (3-151) months. The
study population was 88% Caucasian, 67% KPS 90-100, 77%
acute leukemia and only 14% CML, 56% peripheral blood, and
43% non-TBI myeloablative conditioning. Of the total, 20%
were from 1999-2002, 32% 2003-2006, and 49% from 2007-
2011. In the primary analysis, HLA mismatch (6-7/8)
conferred signiﬁcantly increased risk for grade II-IV and III-IV
acute GVHD, chronic GVHD, and TRM, and worsened DFS and
OS compared to HLA matched cases (8/8). Malignancy
relapse was not affected by HLA mismatch at A, B, C, or DRB1.
The 6/8 cases had signiﬁcantly worse TRM than 7/8 cases.
The adverse impact of HLA mismatch on OS was greatest
among those with early or intermediate stage disease. Single
mismatch at HLA-A, B, and C increased the risk for acute
GVHD, TRM, and worsened OS. While single antigen
mismatch at HLA-B increased risk for grade II-IV acute GVHD
over single allele mismatch at eB, no other differences were
detected between allele or antigen mismatch. Among 8/8
matched cases, DPB1 mismatch was associated with
increased grade II-IV and III-IV acute GVHD and decreased
relapse, and DQB1 mismatch was associated with increased
grade II-IV acute GVHD; these effects were not observed
among 7/8 cases. DPB1 and DQB1 mismatch among 7/8 or 8/
8 cases had no effect on OS or DFS.
Conclusions: Despite improvements in survival after unre-
lated donor HCT over time, donor-recipient HLA disparity
remains a major source of GVHD and mortality.6
Clinical Responses in Patients Infused with T
Lymphocytes Redirected to Target Kappa-Light
Immunoglobulin Chain
Carlos A. Ramos 1,2, Barbara Savoldo 3,4, Enli Liu 3,
Adrian P. Gee 4,5, Zhuyong Mei 3, Bambi Grilley 3,4,
Cliona M. Rooney 3,4, Helen E. Heslop 2,3,4,
Malcolm K. Brenner 2,3,4, Gianpietro Dotti 3. 1Center for Cell
and Gene Therapy, Dept. of Medicine, Baylor College of
Medicine, Houston Methodist Hospital and Texas Children’s
Hospital, Houston, TX; 2Houston Methodist Hospital, Houston,
TX; 3Center for Cell and Gene Therapy, Baylor College of
Medicine, Houston, TX; 4Texas Children’s Hospital, Houston, TX;
5Center for Cell and Gene Therapy, Baylor College of Medicine,
Houston Methodist Hospital and Texas Children’s Hospital,
Houston, TX
Adoptive transfer of T cells with a CD19-speciﬁc chimeric an-
tigen receptor (CAR) to treat B-cell malignancies shows
remarkable clinical efﬁcacy.However, long-termpersistenceof
T cells targeting CD19, a pan-B cell marker, causes depletion
of normal B cells and consequent severe hypogammaglobu-
linemia. In order to target B-cellmalignanciesmore selectively,
we have taken advantage of the clonal restriction of mature
B-cell malignancies, which express either a k or a l-light
immunoglobulin chain.Wegenerated aCAR speciﬁc for k-light
chain (CAR.k) to selectively targetk+ lymphoma/leukemia cells,
while sparing the normal B cells expressing the non-targeted
l-light chain, thus minimizing the impairment of humoral
immunity. After validation in preclinical experiments, we
designed a phase I clinical trial in which patients with re-
fractory/relapsed k+ NHL/CLL are infused with autologous T
cells expressing a CAR.k that includes a CD28 costimulatory
domain. The protocol also allows for the inclusion of patients
with multiple myeloma (MM) with the aim of targeting pu-
tativemyeloma initiating cells. Threedose levels (DL) are being
assessed: 0.2 (DL1), 1 (DL2) and 2 (DL3) 108 T cells/m2.
Tcellsweregenerated for 13patients byactivating autologous
PBMC with OKT3 (n¼5) or CD3/CD28 monoclonal antibodies
(n¼8). In 2 patients with >95% circulating CLL cells, CD3
positive selection was performed using CliniMACS. After
transduction, T cells (1.21070.5107) were expanded ex
vivo for 184 days in the presence of IL-2 to reach sufﬁcient
numbers for dose escalation. CARexpressionwas 81%13%by
ﬂow cytometry. Products were composed predominantly of
CD8+ cells (78%10%). CAR+ T cells speciﬁcally targeted k+
tumors (speciﬁc lysis by 51Cr release 79%10%, 20:1 E:T ratio)
but not ke tumors (11%7%) or theNK-sensitive cell line K562
(26%13%). Ten patients were treated so far: 2 on DL1, 3 on
DL2 and 5 onDL3. Any other treatmentswere discontinued at
least 4 weeks prior to T-cell infusion and patients with ALC
>500 received 12.5 mg/kg cyclophosphamide 4 days before
infusion. Infusions werewell toleratedwithout side effects. A
CAR.k-speciﬁc Q-PCR assay showed that molecular signals
peaked 1-2 weeks post infusion and remained detectable for
at least 6 weeks and up to 9 months in 1 patient. Of the 5
patients with relapsed NHL, 2 entered complete remission
(after 2 and 3 infusions at DL1 and DL3, respectively), 1 had a
partial response and2progressed; 3/3 patientswithMMhave
had stable disease for 2,11 and 17months, associatedwith up
to 38% reduction in their paraprotein; and 2/2 patients with
CLL progressed before or shortly after the 6 week evaluation.
In conclusion, our data indicate that infusion of CAR.k+ T cells
is safe at every DL and can be effective in patients with k+
lymphoma.
